JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
The Motley Fool ·
Key points
- The Wegovy pill has accumulated more than eight million prescriptions since its launch, reflecting strong market adoption in the quarter.
- Novo Nordisk reported a 9% year‑over‑year drop in operating profit in Q3, a consequence the company attributes to its strategic transition toward a high‑volume, low‑price business model.
- Management expects the pill’s performance to validate the company’s pivot, but the near‑term earnings trajectory remains pressured as lower prices weigh on revenues.
- Competitive dynamics include Eli Lilly’s GLP‑1 pill and other entrants, which heighten the emphasis on sustaining adoption and market share.
- The stock has fallen about 70% from its 2024 peak, yet offers a 4.4% dividend yield and valuation measures (P/S, P/E, P/B) below five‑year averages, making it attractive to income/value investors on a longer horizon.
- Analysts at JPMorgan expressed confidence ahead of the earnings report, framing Wegovy’s pill momentum as a positive indicator for the company’s transition strategy.
Summary
Novo Nordisk delivered strong uptake for the Wegovy pill in the latest quarter, underscoring momentum in a growing GLP-1 weight‑loss market while signaling a broader strategic shift toward a high‑volume, low‑price model. Profitability declined 9% year over year as the company prioritizes volume and transition costs over near-term earnings. The results come amid competitive pressure from Eli Lilly and other entrants, and despite the stock’s steep 70% decline from its 2024 peak, the dividend yield remains attractive. Investors face a careful trade‑off: continued pill adoption vs. a lag in profit realization, with a cautious stance warranted until profitability aligns with sales. The outlook hinges on whether the profitability recovery will materialize as the company scales its new model.
This summary was written with AI. The full story has every detail.